1. Home
  2. Analysis
  3. Eliquis
  4. Garcinia

Eliquis and Garcinia drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eliquis and Garcinia. Common interactions include haemorrhage among females and haemoglobin decreased among males.

The phase IV clinical study analyzes what interactions people who take Eliquis and Garcinia have. It is created by eHealthMe based on reports of 10 people who take Eliquis and Garcinia from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 03, 2023

10 people who take Eliquis and Garcinia together, and have interactions are studied.

What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 143,893 Eliquis users for its effectiveness, alternative drugs and more.

What is Garcinia?

Garcinia has active ingredients of garcinia. It is often used in weight loss. eHealthMe is studying from 812 Garcinia users for its effectiveness, alternative drugs and more.

Number of Eliquis and Garcinia reports submitted per year:

Eliquis and Garcinia drug interactions.

Common Eliquis and Garcinia drug interactions by gender *:

female:

  1. Haemorrhage
  2. Multiple sclerosis relapse
  3. Musculoskeletal stiffness
  4. Nasal congestion
  5. Peripheral swelling
  6. Peroneal nerve palsy
  7. Pulmonary arterial hypertension
  8. Rhinitis
  9. Sensory disturbance
  10. Drug ineffective

male:

  1. Haemoglobin decreased
  2. Peripheral swelling
  3. Skin discolouration

Common Eliquis and Garcinia drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Multiple sclerosis relapse

50-59:

n/a

60+:

  1. Asthma
  2. Chest discomfort
  3. Drug ineffective
  4. Dyspnoea
  5. Fatigue
  6. Gastrooesophageal reflux disease
  7. Haemorrhage
  8. Nasal congestion
  9. Peripheral swelling
  10. Pulmonary arterial hypertension

Common conditions people have *:

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 50.00%
  2. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 30.00%
  3. Asthma: 2 people, 20.00%
  4. Gait Disturbance: 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Eliquis and Garcinia?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Eliquis and Garcinia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Eliquis side effects:

Browse all side effects of Eliquis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Eliquis interactions:

Browse all interactions between Eliquis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Garcinia interactions:

Browse all interactions between Garcinia and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on apixaban and garcinia (the active ingredients of Eliquis and Garcinia, respectively), and Eliquis and Garcinia (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Eliquis and Garcinia.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.